General AML,   TP53,  FLT3,  IDH1/2

Lars Bullinger | EHA 2018 | What are the clinical implications of mutations in AML?


At the 23rd Congress of the European Association of Hematology, Lars Bullinger from Charite Universitätsmedizin Berlin, Berlin, DE, discusses the clinical impact of mutations in acute myeloid leukemia (AML). He highlighted that mutational burden can affect the outcomes of AML patients. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF